Recent Updates
Recently added Catalysts
LONA Positive Sentiment

LeonaBio to Participate in Cantor Global Healthcare Conference 2026

Key Takeaway: LeonaBio, a clinical-stage biopharmaceutical company, will participate in the Cantor Global Healthcare Conference 2026 from September 9-11 in New York. The company's management will engage in a fireside chat on September 11, discussing their innovative therapies for diseases with high unmet medical needs. A live webcast will be available for investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • LeonaBio is participating in a significant healthcare conference.
  • The company focuses on developing therapies for high unmet medical needs.
  • Their lead drug candidates target serious conditions like metastatic breast cancer and ALS.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~9 mo
Medium dilution risk
Lead asset
ATH-1017
Phase 2 · Alzheimer Disease

Full Press Release Details

BOTHELL, Wash., Sept. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that Company management will participate in the Cantor Global Healthcare Conference 2026, taking place September 9-11, 2026 in New York, NY. Details are as follows:
Cantor Global Healthcare Conference 2026 Format: Fireside Chat Date and Time: Friday, September 11, 2026, from 9:45 am – 10:15 am EDT Location: New York, NY
A live webcast of the fireside chat can be accessed from the Investors section of the LeonaBio website at https://investors.leonabio.com/news-and-events/events-and-presentations-investor. An archived replay will be available for at least 30 days following the event.
About LeonaBio LeonaBio, headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patients’ lives. Our lead drug candidates, lasofoxifene and brelgometon (ATH-1105), are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. With a strong commitment to scientific excellence and patient-centered innovation, we are dedicated to developing meaningful new therapies for those who need them most.
For more information, visit www.leonabio.com.

Investor & Media Contact: Julie Rathbun LeonaBio Julie.rathbun@leonabio.com 206-769-9219

Frequently Asked Questions

When is the Cantor Global Healthcare Conference 2026?

The conference will take place from September 9-11, 2026.

What will LeonaBio discuss at the conference?

LeonaBio will participate in a fireside chat discussing their innovative therapies.

How can I access the webcast of the event?

The live webcast can be accessed from the Investors section of LeonaBio's website.

What diseases does LeonaBio focus on?

LeonaBio focuses on diseases with high unmet medical needs, including ALS and metastatic breast cancer.

Last updated: Sep 3, 2026